Authors
Savas Gokcek, Busra Kanbur, Ozge Yetginoglu, Ahmet Melih Arslan, Mehmet Uzun, Ilkay Tugba Unek
Published in
Future oncology (London, England). Pages 1-8. Jul 17, 2026. Epub Jul 17, 2026.
Abstract
To evaluate the prognostic significance of the Lung Immune Prognostic Index (LIPI) in patients with metastatic gastric cancer (mGC).
We retrospectively analyzed 177 patients with mGC. Patients were stratified into three groups (good, intermediate, and poor) based on the LIPI score, which was calculated using a derived neutrophil-to-lymphocyte ratio (dNLR) >3 and lactate dehydrogenase (LDH) >upper limit of normal (ULN). Survival outcomes were analyzed using Kaplan-Meier and Cox regression models.
In univariate analyses, intermediate and poor LIPI, elevated dNLR and LDH, ECOG performance status ≥1, low albumin, and high CRP were significantly associated with overall survival. In multivariate analysis, poor LIPI remained an independent prognostic factor (HR: 3.43; 95% CI: 1.30-9.05; p = 0.013). ECOG performance status and C-reactive protein (CRP) were also independently associated with survival. Subgroup analysis showed a more pronounced prognostic impact of LIPI in Human Epidermal Growth Factor Receptor 2 (HER2)-negative patients.
The LIPI is a simple, noninvasive, and inexpensive tool that provides strong prognostic information for patients with mGC, potentially aiding in better risk stratification in clinical practice.
PMID:
42469963
Bibliographic data and abstract were imported from PubMed on 18 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0